ClinicalTrials.gg
CompletedNCT03020160HAVEN 4Updated Jan 11, 2023Results posted

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

A Phase 3 interventional study of Emicizumab in Hemophilia A, sponsored by Hoffmann-La Roche. Completed at 17 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-01-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.

Enrollment
9th of 22
48 · median 27
Started
2017
with 1 other
Phase 3
11 of 22
none open now
Registered
4th of 22
by date
Lead sponsor
10 of 22
Hoffmann-La Roche

Among the 22 studies testing emicizumab in Hemophilia A, this one is the 9th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 3, and was the 4th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About emicizumab

emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing emicizumab in Hemophilia A, or all of them as a file.
02

Study summary

This multicenter, open-label, non-randomized study will assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at a dose of 6 milligrams per kilogram (mg/kg) every 4 weeks in participants with hemophilia A with or without inhibitors against factor VIII (FVIII). The study consists of 2 parts: a pharmacokinetic (PK) run-in part followed by an expansion part.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight greater than or equal to (>/=) 40 kilograms (kg) at screening
  • Diagnosis of severe congenital hemophilia A or hemophilia A with FVIII inhibitors
  • Participants using rFVIIa or willing to switch to recombinant activated factor VII (rFVIIa) as primary bypassing agent for the treatment of breakthrough bleeds
  • FVIII inhibitor test during screening with titer results available prior to first administration of study drug
  • Participants without FVIII inhibitors, that is with less than (\<) 0.6 Bethesda unit per milliliter [BU/mL];\< 1.0 BU/mL only for laboratories with an historical sensitivity cutoff for inhibitor detection of 1.0 BU/mL, who completed successful immune tolerance induction (ITI) must have done so at least 5 years before screening and must have no evidence of inhibitor recurrence (permanent or temporary) indicated by detection of an inhibitor greater than (>) 0.6 BU/mL (> 1.0 BU/mL only for laboratories with an historical sensitivity cutoff for inhibitor detection of 1.0 BU/mL) since ITI
  • Adequate hematologic, hepatic, and renal function

Exclusion criteria

Exclusion Criteria:

  • Inherited or acquired bleeding disorder other than hemophilia A
  • Ongoing or planned ITI therapy; participants in whom ITI has failed will be eligible with a 72-hour prior to the first emicizumab administration
  • History of illicit drug or alcohol abuse within 48 weeks prior to screening, in the investigator's judgment
  • Participants who are at high risk for thrombotic microangiopathy (TMA) (for example, have a previous medical or family history of TMA), in the investigator's judgment
  • Previous (within the last 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
  • Other conditions (for example, certain diseases) that may currently increase the risk of bleeding or thrombosis
  • History of associated with monoclonal antibody therapies or components of the emicizumab injection
  • Known infection with cluster of differentiation (CD) 4 cells counts \<200 cells per microliter (cells/mcL)
  • Use of systemic immunomodulators (for example, interferon) at enrollment or planned use during the study, with the exception of anti-retroviral therapy
  • Concomitant disease, condition, significant abnormality on screening evaluations or laboratory tests, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an additional unacceptable risk in administering study drug to the participant
  • Pregnancy or lactation or intention to become pregnant during the study
  • Women with a positive serum pregnancy test result within 7 days prior to initiation of study drug
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Emicizumab: PK Run-in Cohort

    Participants received emicizumab subcutaneously (SC) at a dose of 6 mg/kg once every 4 weeks, with no loading dose, for at least 24 weeks.

    Drug: Emicizumab

  • Experimental
    Emicizumab: Expansion Cohort

    Participants received emicizumab subcutaneously (SC) at a loading dose of 3 mg/kg once every week for the first 4 weeks followed by a maintenance dose of 6 mg/kg emicizumab SC once every 4 weeks for at least 24 weeks.

    Drug: Emicizumab

Interventions

  • Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.

    Also known as: Hemlibra, RO5534262, ACE910

06

What researchers measure

Primary outcomes

  1. Expansion Part: Annualized Bleeding Rate (ABR) for Treated Bleeds

    The number of treated bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.

    Time frame: From Baseline to at least 24 weeks

  2. Expansion Part: Annualized Bleeding Rate (ABR) for All Bleeds

    The number of all bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the "treated bleeds" outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

    Time frame: From Baseline to at least 24 weeks

  3. Expansion Part: Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A bleed is classified as "spontaneous" if there is no other known contributing factor such as trauma or procedure/surgery. A "treated spontaneous bleed" is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.

    Time frame: From Baseline to at least 24 weeks

  4. Expansion Part: Annualized Bleeding Rate (ABR) for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A "joint bleed" is defined as a bleed with type reported as "joint" and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A "treated joint bleed" is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of joint bleeds, excluding bleeds due to surgery/procedure.

    Time frame: From Baseline to at least 24 weeks

  5. Expansion Part: Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds

    The number of treated target joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A "target joint bleed" is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A "treated target joint bleed" is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.

    Time frame: From Baseline to at least 24 weeks

Secondary outcomes

  1. Expansion Part: Change From Baseline to Week 25 in the Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Total Score for Adult Participants (≥18 Years of Age)

    The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 7 points or more on the Total Score was defined as the threshold for a clinically meaningful improvement.

    Time frame: Baseline, Week 25

  2. Expansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Total Score

    The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 7 points or more on the Total Score was defined as the threshold for a clinically meaningful improvement.

    Time frame: Baseline, Week 25

  3. Expansion Part: Change From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score for Adult Participants (≥18 Years of Age)

    The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 10 points or more on the Physical Health Score was defined as the threshold for a clinically meaningful improvement.

    Time frame: Baseline, Week 25

  4. Expansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score

    The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 10 points or more on the Physical Health Score was defined as the threshold for a clinically meaningful improvement.

    Time frame: Baseline, Week 25

  5. Expansion Part: Change From Baseline to Week 25 in the Hemophilia-Quality of Life-Short Form (Haemo-QoL-SF) Questionnaire Total Score for Adolescent Participants (12-17 Years of Age)

    The Haemo-QoL-SF was developed in a series of age-related questionnaires to measure health-related quality of life (HRQoL) in children and adolescents with hemophilia. The short version for older children containing 35 items was selected for adolescents in this study. Items are rated along five response options: never, rarely, sometimes, often, or all the time. This version covers nine dimensions considered relevant for the children's HRQoL (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia, and treatment). Scale scores range from 0 to 100, with lower scores indicating better HRQoL. Given the small number of adolescent participants, the results of the Haemo-QoL-SF questionnaire should be interpreted with caution.

    Time frame: Baseline, Week 25

  6. Expansion Part: Change From Baseline to Week 25 in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score

    The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. An increase in the VAS score of 7 points or greater was defined as the threshold for a meaningful improvement.

    Time frame: Baseline, Week 25

  7. Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire VAS Score

    The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. An increase in the VAS score of 7 points or greater was defined as the threshold for a meaningful improvement.

    Time frame: Baseline, Week 25

  8. Expansion Part: Change From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score

    The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Published weighting systems allow for creation of a single summary score for the Index Utility Score where overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction. An increase in the Index Utility Score of 0.07 points or greater was defined as the threshold for a meaningful improvement.

    Time frame: Baseline, Week 25

  9. Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score

    The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Published weighting systems allow for creation of a single summary score for the Index Utility Score where overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction. An increase in the Index Utility Score of 0.07 points or greater was defined as the threshold for a meaningful improvement.

    Time frame: Baseline, Week 25

  10. Expansion Part: Proportion of Days Away From Work to Expected Days at Work in the Previous Four Weeks

    Participants enrolled in the expansion part of the study reported at each time point the number of days away from work (i.e., days of work missed) and the expected number of days at work in the previous four weeks, which is reported here for each time point as the proportion of the number of days away from work to the expected number of days at work.

    Time frame: Predose at Baseline, Weeks 13 and 25

  11. Expansion Part: Proportion of Days Away From School to Expected Days at School in the Previous Four Weeks

    Participants enrolled in the expansion part of the study reported at each time point the number of days away from school (i.e., days of school missed) and the expected number of days at school in the previous four weeks, which is reported here as the proportion of the number of days away from school to the expected number of days at school.

    Time frame: Predose at Baseline, Weeks 13 and 25

  12. Expansion Part: Number of Days Hospitalized

    Time frame: From Baseline until at least 24 weeks of treatment (median [min-max] observation time: 25.57 [24.1-29.4] weeks)

  13. Expansion Part: Percentage of Participants Who Preferred Either the New Emicizumab Subcutaneous (SC) Treatment or Their Previous Hemophilia Intravenous (IV) Treatment, or Had No Preference, as Assessed Using the Emicizumab Preference Survey

    The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the participant's preference for treatment with intravenous (IV) factor VIIII (FVIII) or subcutaneous (SC) emicizumab, or no preference.

    Time frame: Predose at Week 17

  14. PK Run-In Part: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Emicizumab

    Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25

  15. PK Run-In Part: Maximum Observed Plasma Concentration (Cmax) of Emicizumab

    Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25

  16. PK Run-In Part: Area Under the Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUC[0-tau]) of Emicizumab

    Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25

  17. PK Run-In Part: Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Emicizumab

    Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25

  18. PK Run-In Part: Apparent Plasma Terminal Half-Life (t1/2) of Emicizumab

    Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25

  19. PK Run-In Part: Apparent Clearance (CL/F) of Emicizumab

    Only CL/F is reported after the first dose; the apparent clearance at steady state (CLss/F) is reported after the sixth dose instead. This is because t1/2 was not properly estimated after the first dose due to sampling time and dosing schedule, and dependent PK parameters, such as CL/F, could not be estimated.

    Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25

  20. PK Run-In Part: Plasma Concentration of Emicizumab at Specified Timepoints

    Time frame: Week 1 Day 1 predose and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 6, 7, 8, 9, 11, 13, 15, 17, 19, 21, 22, 23, 24, and 25, and every 12 weeks thereafter to Week 265

  21. Expansion Part: Plasma Concentration of Emicizumab at Specified Timepoints

    Time frame: Predose at Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 37, 49, 61, 73. 85, 97, 109, 121, 133, 145, 157, 169, 181, 193, 205, 217, 229, 241, and 253

  22. Number of Participants With at Least One Adverse Event

    The number of participants experiencing at least one adverse event (AE), including all non-serious and serious AEs, is reported here. According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to the World Health Organization \[WHO\] toxicity grading scale); the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  23. Number of Participants With at Least One Grade ≥3 Adverse Event

    The World Health Organization (WHO) Toxicity Grading Scale was used for assessing adverse event (AE) severity. For AEs that are not specifically listed in the WHO Toxicity Grading Scale, a Grade 3 AE is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a Grade 4 AE is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE; the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  24. Number of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment

    According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to the World Health Organization \[WHO\] toxicity grading scale); the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  25. Number of Participants With at Least One Adverse Event Related to Study Treatment

    According to the ICH guideline for Good Clinical Practice, an adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. In order to assess the causality of an AE, investigators used their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE is considered to be related to the study drug, indicating "yes" or "no" accordingly.

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  26. Number of Participants With at Least One Adverse Event of Changes From Baseline in Vital Signs

    The number of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. All of the adverse events reported here were assessed independently by the investigator as not related to treatment with emicizumab.

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  27. Number of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings

    Post-baseline physical examination abnormalities that were not present at baseline or worsened were reported as adverse events.

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  28. Number of Participants With at Least One Shift in Clinical Laboratory Parameters From Baseline World Health Organization (WHO) Toxicity Scale Grade 0-2 to Post-Baseline WHO Grade 3 or 4

    An abnormal laboratory value was defined as a laboratory test result outside of the normal range for hematology or serum chemistry parameters. The WHO toxicity grading scale, which ranges from Grades 1 to 4 (least severe to most severe, respectively; Grade 0 is within normal range), was used for assessing the severity of laboratory abnormalities and adverse events (WHO 2003). Not every laboratory abnormality qualified as an adverse event; an abnormality was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. In this study, any laboratory value changes were transient and returned to baseline for all participants.

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  29. Number of Participants With at Least One Local Injection-Site Reaction

    Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an "injection-site reaction" on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a "local injection-site reaction."

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  30. Number of Participants With at Least One Thromboembolic Event

    Hypercoagulation and thromboembolic events were to be reported as serious adverse events or adverse events of special interest. Healthcare providers educated patients/caregivers to recognize the signs and symptoms of potential thromboembolism (i.e., dyspnea, chest pain, leg pain or swelling, etc.) and to ensure that they understood the importance of seeking appropriate medical attention.

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  31. Number of Participants With at Least One Thrombotic Microangiopathy

    Thrombotic microangiopathy is used to describe a group of disorders with clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage that can include the kidneys, gastrointestinal system, or central nervous system, etc. Thrombotic microangiopathy events were to be reported as serious adverse events or adverse events of special interest.

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  32. Number of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction

    Since emicizumab is a biological product, acute, systemic hypersensitivity reactions, including anaphylaxis and anaphylactic reactions, may occur. These events were to be reported as serious adverse events or adverse events of special interest. Healthcare providers (HCP) instructed patients and caregivers how to recognize the signs and symptoms of hypersensitivity, anaphylactic, and anaphylactoid reactions and to contact an HCP or seek emergency care in case of any such occurrence.

    Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)

  33. Number of Participants With Anti-Drug Antibodies to Emicizumab at Any Time Post-Baseline During the Study

    A validated enzyme-linked immunosorbent assay (ELISA) method was used to analyze the levels of anti-drug antibodies (ADAs) to emicizumab in blood plasma samples. Participants were considered ADA-positive if they were ADA-negative at baseline but developed an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 4-fold greater (i.e., ≥ 0.60 titer units) than the titer of the baseline sample (treatment-enhanced ADA response).

    Time frame: Baseline, Weeks 5, 9, 13, 17, 21, and 25, and every 12 weeks thereafter until study completion (up to 5 years, 5 months)

  34. Number of Participants With De Novo Development of Anti-Factor VIII (FVIII) Antibodies

    The levels of anti-FVIII antibodies (inhibitors) were analyzed using a validated FVIII activity assay. A participant was considered to have developed de novo FVIII inhibitors if the inhibitor levels detected in a post-baseline sample reached or exceeded a pre-determined threshold.

    Time frame: Baseline, Weeks 9 and 17 (for non-inhibitor subjects only), Week 25, and every 12 weeks thereafter until study completion (up to 5 years, 5 months)

  35. Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds

    The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

    Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 191.14 [28.0-264.4] weeks)

  36. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds

    The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

    Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 191.14 [28.0-264.4] weeks)

  37. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds

    The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

    Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 191.14 [28.0-264.4] weeks)

  38. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time

    The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks

  39. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time

    The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks

  40. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time

    The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks

  41. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time

    The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks

  42. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time

    The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks

  43. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time

    The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks

07

Results

Posted Dec 26, 2018
Limitations and caveats
Given the small number of adolescent participants, the results of the Haemo-QoL-SF questionnaire should be interpreted with caution.

Participant flow

Participant flow — Overall Study
MilestoneEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Started741
Completed 24 weeks in the study741
Emicizumab dose was up-titrated04
Opted for a change in emicizumab dosing regimen01
Completed641
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryExpansion Part: Annualized Bleeding Rate (ABR) for Treated Bleeds

The number of treated bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.

Time frame:
From Baseline to at least 24 weeks
Reported as:
Number · treated bleed rate per year
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Bleeds
treated bleed rate per yearEmicizumab: Expansion Cohort
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Bleeds2.4 (1.38 to 4.28)
PrimaryExpansion Part: Annualized Bleeding Rate (ABR) for All Bleeds

The number of all bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the "treated bleeds" outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

Time frame:
From Baseline to at least 24 weeks
Reported as:
Number · all bleed rate per year
Expansion Part: Annualized Bleeding Rate (ABR) for All Bleeds
all bleed rate per yearEmicizumab: Expansion Cohort
Expansion Part: Annualized Bleeding Rate (ABR) for All Bleeds4.5 (3.10 to 6.60)
PrimaryExpansion Part: Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A bleed is classified as "spontaneous" if there is no other known contributing factor such as trauma or procedure/surgery. A "treated spontaneous bleed" is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.

Time frame:
From Baseline to at least 24 weeks
Reported as:
Number · treated spontaneous bleed rate per year
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds
treated spontaneous bleed rate per yearEmicizumab: Expansion Cohort
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds0.6 (0.27 to 1.53)
PrimaryExpansion Part: Annualized Bleeding Rate (ABR) for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A "joint bleed" is defined as a bleed with type reported as "joint" and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A "treated joint bleed" is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of joint bleeds, excluding bleeds due to surgery/procedure.

Time frame:
From Baseline to at least 24 weeks
Reported as:
Number · treated joint bleed rate per year
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Joint Bleeds
treated joint bleed rate per yearEmicizumab: Expansion Cohort
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Joint Bleeds1.7 (0.82 to 3.68)
PrimaryExpansion Part: Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds

The number of treated target joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A "target joint bleed" is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A "treated target joint bleed" is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.

Time frame:
From Baseline to at least 24 weeks
Reported as:
Number · treated target joint bleed rate per year
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds
treated target joint bleed rate per yearEmicizumab: Expansion Cohort
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds1.0 (0.31 to 3.26)
SecondaryExpansion Part: Change From Baseline to Week 25 in the Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Total Score for Adult Participants (≥18 Years of Age)

The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 7 points or more on the Total Score was defined as the threshold for a clinically meaningful improvement.

Time frame:
Baseline, Week 25
Reported as:
Mean · units on a scale
Expansion Part: Change From Baseline to Week 25 in the Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Total Score for Adult Participants (≥18 Years of Age)
units on a scaleEmicizumab: Expansion Cohort
Expansion Part: Change From Baseline to Week 25 in the Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Total Score for Adult Participants (≥18 Years of Age)-13.62 (-18.36 to -8.88)
SecondaryExpansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Total Score

The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 7 points or more on the Total Score was defined as the threshold for a clinically meaningful improvement.

Time frame:
Baseline, Week 25
Reported as:
Number · percentage of participants
Expansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Total Score
percentage of participantsEmicizumab: Expansion Cohort
Expansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Total Score67.6
SecondaryExpansion Part: Change From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score for Adult Participants (≥18 Years of Age)

The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 10 points or more on the Physical Health Score was defined as the threshold for a clinically meaningful improvement.

Time frame:
Baseline, Week 25
Reported as:
Mean · units on a scale
Expansion Part: Change From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score for Adult Participants (≥18 Years of Age)
units on a scaleEmicizumab: Expansion Cohort
Expansion Part: Change From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score for Adult Participants (≥18 Years of Age)-15.14 (-22.44 to -7.83)
SecondaryExpansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score

The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 10 points or more on the Physical Health Score was defined as the threshold for a clinically meaningful improvement.

Time frame:
Baseline, Week 25
Reported as:
Number · percentage of participants
Expansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score
percentage of participantsEmicizumab: Expansion Cohort
Expansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score67.6
SecondaryExpansion Part: Change From Baseline to Week 25 in the Hemophilia-Quality of Life-Short Form (Haemo-QoL-SF) Questionnaire Total Score for Adolescent Participants (12-17 Years of Age)

The Haemo-QoL-SF was developed in a series of age-related questionnaires to measure health-related quality of life (HRQoL) in children and adolescents with hemophilia. The short version for older children containing 35 items was selected for adolescents in this study. Items are rated along five response options: never, rarely, sometimes, often, or all the time. This version covers nine dimensions considered relevant for the children's HRQoL (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia, and treatment). Scale scores range from 0 to 100, with lower scores indicating better HRQoL. Given the small number of adolescent participants, the results of the Haemo-QoL-SF questionnaire should be interpreted with caution.

Time frame:
Baseline, Week 25
Reported as:
Mean · units on a scale
Expansion Part: Change From Baseline to Week 25 in the Hemophilia-Quality of Life-Short Form (Haemo-QoL-SF) Questionnaire Total Score for Adolescent Participants (12-17 Years of Age)
units on a scaleEmicizumab: Expansion Cohort
Expansion Part: Change From Baseline to Week 25 in the Hemophilia-Quality of Life-Short Form (Haemo-QoL-SF) Questionnaire Total Score for Adolescent Participants (12-17 Years of Age)-8.10 ± 6.48
SecondaryExpansion Part: Change From Baseline to Week 25 in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score

The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. An increase in the VAS score of 7 points or greater was defined as the threshold for a meaningful improvement.

Time frame:
Baseline, Week 25
Reported as:
Mean · units on a scale
Expansion Part: Change From Baseline to Week 25 in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score
units on a scaleEmicizumab: Expansion Cohort
Expansion Part: Change From Baseline to Week 25 in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score5.53 (1.15 to 9.90)
SecondaryExpansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire VAS Score

The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. An increase in the VAS score of 7 points or greater was defined as the threshold for a meaningful improvement.

Time frame:
Baseline, Week 25
Reported as:
Number · percentage of participants
Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire VAS Score
percentage of participantsEmicizumab: Expansion Cohort
Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire VAS Score35.0
SecondaryExpansion Part: Change From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score

The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Published weighting systems allow for creation of a single summary score for the Index Utility Score where overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction. An increase in the Index Utility Score of 0.07 points or greater was defined as the threshold for a meaningful improvement.

Time frame:
Baseline, Week 25
Reported as:
Mean · units on a scale
Expansion Part: Change From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score
units on a scaleEmicizumab: Expansion Cohort
Expansion Part: Change From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score0.06 (0.03 to 0.10)
SecondaryExpansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score

The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Published weighting systems allow for creation of a single summary score for the Index Utility Score where overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction. An increase in the Index Utility Score of 0.07 points or greater was defined as the threshold for a meaningful improvement.

Time frame:
Baseline, Week 25
Reported as:
Number · percentage of participants
Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score
percentage of participantsEmicizumab: Expansion Cohort
Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score47.5
SecondaryExpansion Part: Proportion of Days Away From Work to Expected Days at Work in the Previous Four Weeks

Participants enrolled in the expansion part of the study reported at each time point the number of days away from work (i.e., days of work missed) and the expected number of days at work in the previous four weeks, which is reported here for each time point as the proportion of the number of days away from work to the expected number of days at work.

Time frame:
Predose at Baseline, Weeks 13 and 25
Reported as:
Mean · away/expected work days
Expansion Part: Proportion of Days Away From Work to Expected Days at Work in the Previous Four Weeks
away/expected work daysEmicizumab: Expansion Cohort
Baseline0.05 (0.01 to 0.10)
Week 130.00 (0.00 to 0.00)
Week 250.01 (0.00 to 0.02)
SecondaryExpansion Part: Proportion of Days Away From School to Expected Days at School in the Previous Four Weeks

Participants enrolled in the expansion part of the study reported at each time point the number of days away from school (i.e., days of school missed) and the expected number of days at school in the previous four weeks, which is reported here as the proportion of the number of days away from school to the expected number of days at school.

Time frame:
Predose at Baseline, Weeks 13 and 25
Reported as:
Mean · away/expected school days
Expansion Part: Proportion of Days Away From School to Expected Days at School in the Previous Four Weeks
away/expected school daysEmicizumab: Expansion Cohort
Baseline0.12 (0.01 to 0.24)
Week 130.00 (0.00 to 0.00)
Week 250.03 (0.00 to 0.10)
SecondaryExpansion Part: Number of Days Hospitalized
Time frame:
From Baseline until at least 24 weeks of treatment (median [min-max] observation time: 25.57 [24.1-29.4] weeks)
Reported as:
Mean · days
Expansion Part: Number of Days Hospitalized
daysEmicizumab: PK Run-In Cohort
Expansion Part: Number of Days Hospitalized0 ± 0
SecondaryExpansion Part: Percentage of Participants Who Preferred Either the New Emicizumab Subcutaneous (SC) Treatment or Their Previous Hemophilia Intravenous (IV) Treatment, or Had No Preference, as Assessed Using the Emicizumab Preference Survey

The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the participant's preference for treatment with intravenous (IV) factor VIIII (FVIII) or subcutaneous (SC) emicizumab, or no preference.

Time frame:
Predose at Week 17
Reported as:
Number · percentage of participants
Expansion Part: Percentage of Participants Who Preferred Either the New Emicizumab Subcutaneous (SC) Treatment or Their Previous Hemophilia Intravenous (IV) Treatment, or Had No Preference, as Assessed Using the Emicizumab Preference Survey
percentage of participantsEmicizumab: PK Run-In Cohort
Prefer the New Emicizumab SC Treatment100 (91.40 to 100.00)
Prefer My Old Hemophilia Treatment (IV)0.0 (0.00 to 8.60)
Have No Preference0.0 (0.00 to 8.60)
SecondaryPK Run-In Part: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Emicizumab
Time frame:
Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
Reported as:
Median · day
PK Run-In Part: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Emicizumab
dayEmicizumab: PK Run-In Cohort
After First Dose (Weeks 1-5)6.95 (3.99 to 7.18)
After Sixth Dose (Weeks 21-25)6.98 (6.90 to 14.03)
SecondaryPK Run-In Part: Maximum Observed Plasma Concentration (Cmax) of Emicizumab
Time frame:
Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
Reported as:
Geometric mean · μg/mL
PK Run-In Part: Maximum Observed Plasma Concentration (Cmax) of Emicizumab
μg/mLEmicizumab: PK Run-In Cohort
After First Dose (Weeks 1-5)31.8 ± 19.3
After Sixth Dose (Weeks 21-25)62.7 ± 17.3
SecondaryPK Run-In Part: Area Under the Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUC[0-tau]) of Emicizumab
Time frame:
Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
Reported as:
Geometric mean · day*μg/mL
PK Run-In Part: Area Under the Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUC[0-tau]) of Emicizumab
day*μg/mLEmicizumab: PK Run-In Cohort
After First Dose (Weeks 1-5)663 ± 19.6
After Sixth Dose (Weeks 21-25)1420 ± 20.7
SecondaryPK Run-In Part: Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Emicizumab
Time frame:
Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
Reported as:
Geometric mean · day*μg/mL
PK Run-In Part: Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Emicizumab
day*μg/mLEmicizumab: PK Run-In Cohort
After First Dose (Weeks 1-5)1490 ± 27.2
SecondaryPK Run-In Part: Apparent Plasma Terminal Half-Life (t1/2) of Emicizumab
Time frame:
Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
Reported as:
Geometric mean · day
PK Run-In Part: Apparent Plasma Terminal Half-Life (t1/2) of Emicizumab
dayEmicizumab: PK Run-In Cohort
After First Dose (Weeks 1-5)29.5 ± 38.5
SecondaryPK Run-In Part: Apparent Clearance (CL/F) of Emicizumab

Only CL/F is reported after the first dose; the apparent clearance at steady state (CLss/F) is reported after the sixth dose instead. This is because t1/2 was not properly estimated after the first dose due to sampling time and dosing schedule, and dependent PK parameters, such as CL/F, could not be estimated.

Time frame:
Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
Reported as:
Geometric mean · mL/h
PK Run-In Part: Apparent Clearance (CL/F) of Emicizumab
mL/hEmicizumab: PK Run-In Cohort
After First Dose (Weeks 1-5)10.7 ± 23.9
After Sixth Dose (Weeks 21-25)11.1 ± 20.8
SecondaryPK Run-In Part: Plasma Concentration of Emicizumab at Specified Timepoints
Time frame:
Week 1 Day 1 predose and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 6, 7, 8, 9, 11, 13, 15, 17, 19, 21, 22, 23, 24, and 25, and every 12 weeks thereafter to Week 265
Reported as:
Geometric mean · μg/mL
PK Run-In Part: Plasma Concentration of Emicizumab at Specified Timepoints
μg/mLEmicizumab: PK Run-In Cohort
Week 1, Day 1 - PredoseNA ± NA
Week 1, Day 1 - 8 hours7.0 ± 71.7
Week 1, Day 320.6 ± 51.2
Week 1, Day 526.5 ± 29.7
Week 2, Day 829.4 ± 25.1
Week 2, Day 1127.7 ± 21.9
Week 3, Day 1526.3 ± 20.5
Week 3, Day 1824.1 ± 21.6
Week 4, Day 2222.0 ± 14.8
Week 4, Day 2520.6 ± 15.6
Week 518.5 ± 18.2
Week 647.4 ± 13.8
Week 742.1 ± 18.3
Week 835.4 ± 22.5
Week 928.2 ± 18.6
Week 1155.9 ± 20.4
Week 1334.6 ± 24.1
Week 1552.0 ± 17.0
Week 1736.7 ± 16.1
Week 1950.8 ± 32.6
Week 2134.5 ± 25.1
Week 2262.2 ± 17.5
Week 2356.5 ± 19.0
Week 2447.9 ± 28.7
Week 2539.2 ± 25.3
Week 3734.0 ± 15.8
Week 4934.7 ± 23.2
Week 6141.1 ± 25.9
Week 7339.7 ± 22.8
Week 8538.0 ± 29.2
Week 9743.6 ± 17.1
Week 10937.7 ± 13.8
Week 12139.6 ± 19.8
Week 13337.5 ± 14.2
Week 14534.8 ± 13.1
Week 15735.0 ± 20.7
Week 18145.4 ± 14.6
Week 19337.9 ± 21.5
Week 20545.4 ± 21.0
Week 21745.3 ± 11.3
Week 22952.1 ± 18.6
Week 24145.6 ± 13.6
Week 25340.4 ± 13.8
Week 26542.4 ± 16.5
SecondaryExpansion Part: Plasma Concentration of Emicizumab at Specified Timepoints
Time frame:
Predose at Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 37, 49, 61, 73. 85, 97, 109, 121, 133, 145, 157, 169, 181, 193, 205, 217, 229, 241, and 253
Reported as:
Geometric mean · μg/mL
Expansion Part: Plasma Concentration of Emicizumab at Specified Timepoints
μg/mLEmicizumab: Expansion Cohort
Week 1NA ± NA
Week 216.0 ± 36.8
Week 329.8 ± 30.5
Week 441.3 ± 32.4
Week 548.8 ± 32.2
Week 940.4 ± 45.7
Week 1338.9 ± 49.1
Week 1736.1 ± 53.8
Week 2137.4 ± 48.3
Week 2537.6 ± 52.5
Week 3739.6 ± 49.9
Week 4940.2 ± 48.4
Week 6138.7 ± 51.7
Week 7342.1 ± 51.2
Week 8536.4 ± 50.8
Week 9735.6 ± 49.5
Week 10933.0 ± 63.6
Week 12132.5 ± 60.5
Week 13333.7 ± 49.0
Week 14536.5 ± 51.7
Week 15747.3 ± 36.0
Week 16941.7 ± 41.9
Week 18145.1 ± 47.9
Week 19348.6 ± 47.0
Week 20546.0 ± 48.2
Week 21743.9 ± 47.8
Week 22950.2 ± 43.1
Week 24136.2 ± 46.5
Week 25338.8 ± 46.6
SecondaryNumber of Participants With at Least One Adverse Event

The number of participants experiencing at least one adverse event (AE), including all non-serious and serious AEs, is reported here. According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to the World Health Organization \[WHO\] toxicity grading scale); the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Any Adverse Event (AE)739
Serious AE28
SecondaryNumber of Participants With at Least One Grade ≥3 Adverse Event

The World Health Organization (WHO) Toxicity Grading Scale was used for assessing adverse event (AE) severity. For AEs that are not specifically listed in the WHO Toxicity Grading Scale, a Grade 3 AE is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a Grade 4 AE is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE; the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Grade ≥3 Adverse Event
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Number of Participants With at Least One Grade ≥3 Adverse Event27
SecondaryNumber of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment

According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to the World Health Organization \[WHO\] toxicity grading scale); the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Number of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment00
SecondaryNumber of Participants With at Least One Adverse Event Related to Study Treatment

According to the ICH guideline for Good Clinical Practice, an adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. In order to assess the causality of an AE, investigators used their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE is considered to be related to the study drug, indicating "yes" or "no" accordingly.

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event Related to Study Treatment
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Any Adverse Event Related to Study Treatment214
Injection Site Reaction19
Chills01
Presyncope01
Rash01
Erythema01
Incorrect Dose Administered01
Accidental Overdose01
Iron Deficiency Anaemia10
SecondaryNumber of Participants With at Least One Adverse Event of Changes From Baseline in Vital Signs

The number of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. All of the adverse events reported here were assessed independently by the investigator as not related to treatment with emicizumab.

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event of Changes From Baseline in Vital Signs
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Hypertension24
Pyrexia14
Tachycardia01
SecondaryNumber of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings

Post-baseline physical examination abnormalities that were not present at baseline or worsened were reported as adverse events.

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Number of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings00
SecondaryNumber of Participants With at Least One Shift in Clinical Laboratory Parameters From Baseline World Health Organization (WHO) Toxicity Scale Grade 0-2 to Post-Baseline WHO Grade 3 or 4

An abnormal laboratory value was defined as a laboratory test result outside of the normal range for hematology or serum chemistry parameters. The WHO toxicity grading scale, which ranges from Grades 1 to 4 (least severe to most severe, respectively; Grade 0 is within normal range), was used for assessing the severity of laboratory abnormalities and adverse events (WHO 2003). Not every laboratory abnormality qualified as an adverse event; an abnormality was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. In this study, any laboratory value changes were transient and returned to baseline for all participants.

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Shift in Clinical Laboratory Parameters From Baseline World Health Organization (WHO) Toxicity Scale Grade 0-2 to Post-Baseline WHO Grade 3 or 4
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Aspartate Aminotransferase (AST) - High01
Calcium, Corrected - Low01
Phosphorus - Low02
Sodium - High01
SecondaryNumber of Participants With at Least One Local Injection-Site Reaction

Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an "injection-site reaction" on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a "local injection-site reaction."

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Local Injection-Site Reaction
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Number of Participants With at Least One Local Injection-Site Reaction19
SecondaryNumber of Participants With at Least One Thromboembolic Event

Hypercoagulation and thromboembolic events were to be reported as serious adverse events or adverse events of special interest. Healthcare providers educated patients/caregivers to recognize the signs and symptoms of potential thromboembolism (i.e., dyspnea, chest pain, leg pain or swelling, etc.) and to ensure that they understood the importance of seeking appropriate medical attention.

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Thromboembolic Event
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Number of Participants With at Least One Thromboembolic Event00
SecondaryNumber of Participants With at Least One Thrombotic Microangiopathy

Thrombotic microangiopathy is used to describe a group of disorders with clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage that can include the kidneys, gastrointestinal system, or central nervous system, etc. Thrombotic microangiopathy events were to be reported as serious adverse events or adverse events of special interest.

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Thrombotic Microangiopathy
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Number of Participants With at Least One Thrombotic Microangiopathy00
SecondaryNumber of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction

Since emicizumab is a biological product, acute, systemic hypersensitivity reactions, including anaphylaxis and anaphylactic reactions, may occur. These events were to be reported as serious adverse events or adverse events of special interest. Healthcare providers (HCP) instructed patients and caregivers how to recognize the signs and symptoms of hypersensitivity, anaphylactic, and anaphylactoid reactions and to contact an HCP or seek emergency care in case of any such occurrence.

Time frame:
From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Number of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction00
SecondaryNumber of Participants With Anti-Drug Antibodies to Emicizumab at Any Time Post-Baseline During the Study

A validated enzyme-linked immunosorbent assay (ELISA) method was used to analyze the levels of anti-drug antibodies (ADAs) to emicizumab in blood plasma samples. Participants were considered ADA-positive if they were ADA-negative at baseline but developed an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 4-fold greater (i.e., ≥ 0.60 titer units) than the titer of the baseline sample (treatment-enhanced ADA response).

Time frame:
Baseline, Weeks 5, 9, 13, 17, 21, and 25, and every 12 weeks thereafter until study completion (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies to Emicizumab at Any Time Post-Baseline During the Study
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Number of Participants With Anti-Drug Antibodies to Emicizumab at Any Time Post-Baseline During the Study11
SecondaryNumber of Participants With De Novo Development of Anti-Factor VIII (FVIII) Antibodies

The levels of anti-FVIII antibodies (inhibitors) were analyzed using a validated FVIII activity assay. A participant was considered to have developed de novo FVIII inhibitors if the inhibitor levels detected in a post-baseline sample reached or exceeded a pre-determined threshold.

Time frame:
Baseline, Weeks 9 and 17 (for non-inhibitor subjects only), Week 25, and every 12 weeks thereafter until study completion (up to 5 years, 5 months)
Reported as:
Count of participants · Participants
Number of Participants With De Novo Development of Anti-Factor VIII (FVIII) Antibodies
ParticipantsEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
Number of Participants With De Novo Development of Anti-Factor VIII (FVIII) Antibodies00
SecondaryLong-Term Efficacy of Emicizumab: Model-Based Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds

The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

Time frame:
From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 191.14 [28.0-264.4] weeks)
Reported as:
Number · bleeds per year
Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds
bleeds per yearEmicizumab: Expansion Cohort
Treated Bleeds1.9 (1.22 to 3.02)
All Bleeds2.9 (1.97 to 4.17)
Treated Spontaneous Bleeds0.5 (0.26 to 1.00)
Treated Joint Bleeds1.2 (0.69 to 2.17)
Treated Target Joint Bleeds0.5 (0.24 to 1.26)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds

The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

Time frame:
From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 191.14 [28.0-264.4] weeks)
Reported as:
Mean · bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds
bleeds per yearEmicizumab: Expansion Cohort
Treated Bleeds2.0 (0.25 to 7.28)
All Bleeds3.0 (0.63 to 8.82)
Treated Spontaneous Bleeds0.7 (0.00 to 4.95)
Treated Joint Bleeds1.3 (0.07 to 6.11)
Treated Target Joint Bleeds0.6 (0.00 to 4.77)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds

The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

Time frame:
From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 191.14 [28.0-264.4] weeks)
Reported as:
Median · bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds
bleeds per yearEmicizumab: Expansion Cohort
Treated Bleeds0.6 (0.20 to 2.20)
All Bleeds1.2 (0.60 to 3.78)
Treated Spontaneous Bleeds0.0 (0.00 to 0.59)
Treated Joint Bleeds0.3 (0.00 to 1.22)
Treated Target Joint Bleeds0.0 (0.00 to 0.20)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time

The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Reported as:
Mean · Treated bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time
Treated bleeds per yearEmicizumab: Expansion Cohort
1 to 12 Weeks2.3 (0.35 to 7.75)
13 to 24 Weeks2.5 (0.43 to 8.08)
25 to 36 Weeks1.5 (0.11 to 6.40)
37 to 48 Weeks1.9 (0.23 to 7.14)
49 to 60 Weeks1.3 (0.06 to 6.01)
61 to 72 Weeks2.7 (0.48 to 8.25)
73 to 84 Weeks1.1 (0.04 to 5.72)
85 to 96 Weeks1.4 (0.10 to 6.33)
97 to 108 Weeks2.0 (0.23 to 7.19)
109 to 120 Weeks1.4 (0.08 to 6.22)
121 to 132 Weeks1.8 (0.18 to 6.87)
133 to 144 Weeks1.0 (0.02 to 5.55)
145 to 156 Weeks1.6 (0.13 to 6.55)
157 to 168 Weeks2.0 (0.23 to 7.19)
169 to 180 Weeks2.1 (0.26 to 7.34)
181 to 192 Weeks1.3 (0.07 to 6.09)
193 to 204 Weeks1.7 (0.15 to 6.73)
205 to 216 Weeks1.4 (0.10 to 6.33)
217 to 228 Weeks1.2 (0.05 to 5.93)
229 to 240 Weeks1.0 (0.02 to 5.51)
241 to 252 Weeks2.4 (0.40 to 7.92)
253 to 264 Weeks2.6 (0.46 to 8.17)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time

The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Reported as:
Median · Treated bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time
Treated bleeds per yearEmicizumab: Expansion Cohort
1 to 12 Weeks0.0 (0.00 to 4.35)
13 to 24 Weeks0.0 (0.00 to 4.35)
25 to 36 Weeks0.0 (0.00 to 0.00)
37 to 48 Weeks0.0 (0.00 to 0.00)
49 to 60 Weeks0.0 (0.00 to 0.00)
61 to 72 Weeks0.0 (0.00 to 2.17)
73 to 84 Weeks0.0 (0.00 to 0.00)
85 to 96 Weeks0.0 (0.00 to 0.00)
97 to 108 Weeks0.0 (0.00 to 0.00)
109 to 120 Weeks0.0 (0.00 to 0.00)
121 to 132 Weeks0.0 (0.00 to 0.00)
133 to 144 Weeks0.0 (0.00 to 0.00)
145 to 156 Weeks0.0 (0.00 to 0.00)
157 to 168 Weeks0.0 (0.00 to 0.00)
169 to 180 Weeks0.0 (0.00 to 0.00)
181 to 192 Weeks0.0 (0.00 to 0.00)
193 to 204 Weeks0.0 (0.00 to 0.00)
205 to 216 Weeks0.0 (0.00 to 4.35)
217 to 228 Weeks0.0 (0.00 to 0.00)
229 to 240 Weeks0.0 (0.00 to 0.00)
241 to 252 Weeks0.0 (0.00 to 4.35)
253 to 264 Weeks4.3 (0.00 to 4.35)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time

The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Reported as:
Mean · All bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time
All bleeds per yearEmicizumab: Expansion Cohort
1 to 12 Weeks5.1 (1.67 to 11.80)
13 to 24 Weeks4.0 (1.11 to 10.29)
25 to 36 Weeks3.1 (0.66 to 8.90)
37 to 48 Weeks2.5 (0.42 to 8.03)
49 to 60 Weeks2.2 (0.30 to 7.50)
61 to 72 Weeks3.5 (0.85 to 9.52)
73 to 84 Weeks1.8 (0.17 to 6.85)
85 to 96 Weeks2.0 (0.24 to 7.21)
97 to 108 Weeks2.4 (0.37 to 7.81)
109 to 120 Weeks1.6 (0.13 to 6.55)
121 to 132 Weeks2.2 (0.30 to 7.50)
133 to 144 Weeks1.2 (0.05 to 5.89)
145 to 156 Weeks2.0 (0.23 to 7.19)
157 to 168 Weeks2.0 (0.23 to 7.19)
169 to 180 Weeks2.3 (0.33 to 7.66)
181 to 192 Weeks1.7 (0.17 to 6.81)
193 to 204 Weeks1.9 (0.22 to 7.12)
205 to 216 Weeks1.4 (0.10 to 6.33)
217 to 228 Weeks1.7 (0.15 to 6.73)
229 to 240 Weeks1.0 (0.02 to 5.51)
241 to 252 Weeks2.4 (0.40 to 7.92)
253 to 264 Weeks2.6 (0.46 to 8.17)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time

The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Reported as:
Median · All bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time
All bleeds per yearEmicizumab: Expansion Cohort
1 to 12 Weeks0.0 (0.00 to 8.70)
13 to 24 Weeks4.3 (0.00 to 4.35)
25 to 36 Weeks0.0 (0.00 to 4.35)
37 to 48 Weeks0.0 (0.00 to 0.00)
49 to 60 Weeks0.0 (0.00 to 4.35)
61 to 72 Weeks0.0 (0.00 to 4.35)
73 to 84 Weeks0.0 (0.00 to 4.35)
85 to 96 Weeks0.0 (0.00 to 2.17)
97 to 108 Weeks0.0 (0.00 to 0.00)
109 to 120 Weeks0.0 (0.00 to 0.00)
121 to 132 Weeks0.0 (0.00 to 4.35)
133 to 144 Weeks0.0 (0.00 to 0.00)
145 to 156 Weeks0.0 (0.00 to 0.00)
157 to 168 Weeks0.0 (0.00 to 0.00)
169 to 180 Weeks0.0 (0.00 to 0.00)
181 to 192 Weeks0.0 (0.00 to 0.00)
193 to 204 Weeks0.0 (0.00 to 0.00)
205 to 216 Weeks0.0 (0.00 to 4.35)
217 to 228 Weeks0.0 (0.00 to 0.00)
229 to 240 Weeks0.0 (0.00 to 0.00)
241 to 252 Weeks0.0 (0.00 to 4.35)
253 to 264 Weeks4.3 (0.00 to 4.35)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time

The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Reported as:
Mean · Treated spontaneous bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time
Treated spontaneous bleeds per yearEmicizumab: Expansion Cohort
1 to 12 Weeks0.4 (0.00 to 4.35)
13 to 24 Weeks1.0 (0.02 to 5.49)
25 to 36 Weeks0.1 (0.00 to 3.93)
37 to 48 Weeks0.0 (0 to 3.69)
49 to 60 Weeks0.3 (0.00 to 4.38)
61 to 72 Weeks0.2 (0.00 to 4.18)
73 to 84 Weeks0.1 (0.00 to 3.97)
85 to 96 Weeks0.0 (0 to 3.69)
97 to 108 Weeks0.2 (0.00 to 4.09)
109 to 120 Weeks0.4 (0.00 to 4.48)
121 to 132 Weeks0.4 (0.00 to 4.48)
133 to 144 Weeks0.4 (0.00 to 4.48)
145 to 156 Weeks1.0 (0.02 to 5.55)
157 to 168 Weeks1.8 (0.18 to 6.87)
169 to 180 Weeks0.0 (0 to 3.69)
181 to 192 Weeks0.0 (0 to 3.69)
193 to 204 Weeks0.7 (0.01 to 5.09)
205 to 216 Weeks0.5 (0.00 to 4.64)
217 to 228 Weeks0.0 (0 to 3.69)
229 to 240 Weeks0.2 (0.00 to 4.18)
241 to 252 Weeks0.8 (0.01 to 5.25)
253 to 264 Weeks0.0 (0 to 3.69)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time

The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Reported as:
Median · Treated spontaneous bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time
Treated spontaneous bleeds per yearEmicizumab: Expansion Cohort
1 to 12 Weeks0.0 (0.00 to 0.00)
13 to 24 Weeks0.0 (0.00 to 0.00)
25 to 36 Weeks0.0 (0.00 to 0.00)
37 to 48 Weeks0.0 (0.00 to 0.00)
49 to 60 Weeks0.0 (0.00 to 0.00)
61 to 72 Weeks0.0 (0.00 to 0.00)
73 to 84 Weeks0.0 (0.00 to 0.00)
85 to 96 Weeks0.0 (0.00 to 0.00)
97 to 108 Weeks0.0 (0.00 to 0.00)
109 to 120 Weeks0.0 (0.00 to 0.00)
121 to 132 Weeks0.0 (0.00 to 0.00)
133 to 144 Weeks0.0 (0.00 to 0.00)
145 to 156 Weeks0.0 (0.00 to 0.00)
157 to 168 Weeks0.0 (0.00 to 0.00)
169 to 180 Weeks0.0 (0.00 to 0.00)
181 to 192 Weeks0.0 (0.00 to 0.00)
193 to 204 Weeks0.0 (0.00 to 0.00)
205 to 216 Weeks0.0 (0.00 to 0.00)
217 to 228 Weeks0.0 (0.00 to 0.00)
229 to 240 Weeks0.0 (0.00 to 0.00)
241 to 252 Weeks0.0 (0.00 to 0.00)
253 to 264 Weeks0.0 (0.00 to 0.00)

Adverse events

Collected over From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Emicizumab: PK Run-In Cohort0/7 (0%)2/7 (28.6%)7/7 (100%)
Emicizumab: Expansion Cohort0/41 (0%)8/41 (19.5%)37/41 (90.2%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
CHOLELITHIASIS OBSTRUCTIVEHepatobiliary disorders1/70/41
HYPERTENSIONVascular disorders1/70/41
ATRIAL FIBRILLATIONCardiac disorders0/71/41
TOOTHACHEGastrointestinal disorders0/71/41
CELLULITISInfections and infestations0/71/41
HEAD INJURYInjury, poisoning and procedural complications0/71/41
RHABDOMYOLYSISMusculoskeletal and connective tissue disorders0/71/41
BLADDER NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/71/41
DIFFUSE LARGE B-CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/71/41
TUMOUR COMPRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/71/41
Most frequent other events
Showing 10 of 59
Most frequent other events
EventEmicizumab: PK Run-In CohortEmicizumab: Expansion Cohort
ARTHRALGIAMusculoskeletal and connective tissue disorders4/717/41
HEADACHENervous system disorders4/712/41
OSTEOARTHRITISMusculoskeletal and connective tissue disorders3/71/41
SYNOVITISMusculoskeletal and connective tissue disorders3/72/41
NASOPHARYNGITISInfections and infestations0/714/41
ABDOMINAL PAINGastrointestinal disorders2/72/41
ODYNOPHAGIAGastrointestinal disorders2/70/41
EAR INFECTIONInfections and infestations2/70/41
PHARYNGITISInfections and infestations2/70/41
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/73/41

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Emicizumab: PK Run-In CohortEmicizumab: Expansion CohortTotal
<=18 years134
Between 18 and 65 years63541
>=65 years033
Sex: Female, Male
Sex: Female, Male(Participants)Emicizumab: PK Run-In CohortEmicizumab: Expansion CohortTotal
Female000
Male74148
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Emicizumab: PK Run-In CohortEmicizumab: Expansion CohortTotal
Hispanic or Latino123
Not Hispanic or Latino63844
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Emicizumab: PK Run-In CohortEmicizumab: Expansion CohortTotal
American Indian or Alaska Native000
Asian2810
Native Hawaiian or Other Pacific Islander000
Black or African American011
White53136
More than one race000
Unknown or Not Reported011
Number of Participants with 0, 1, or >1 Target Joints in the Last 24 Weeks Prior to Study Entry
Number of Participants with 0, 1, or >1 Target Joints in the Last 24 Weeks Prior to Study Entry(Participants)Emicizumab: PK Run-In CohortEmicizumab: Expansion CohortTotal
0 Target Joints11617
1 Target Joint2810
>1 Target Joints41721
Number of Participants by Hemophilia A Severity at Baseline
Number of Participants by Hemophilia A Severity at Baseline(Participants)Emicizumab: PK Run-In CohortEmicizumab: Expansion CohortTotal
Mild011
Moderate000
Severe74047
Number of Participants by Factor VIII Inhibitor Status at Baseline
Number of Participants by Factor VIII Inhibitor Status at Baseline(Participants)Emicizumab: PK Run-In CohortEmicizumab: Expansion CohortTotal
Factor VIII Inhibitor Positive358
Factor VIII Inhibitor Negative43640
08

Study locations

17 sites
  • University of California Davis
    Sacramento, California 95817, United States
  • Indiana Hemophilia & Thrombosis center
    Indianapolis, Indiana 46260, United States
  • University of Michigan, C.S. Mott Children's Hospital
    Ann Arbor, Michigan 48109, United States
  • Univ of N Carolina Chapel Hill; Hematology/Oncology
    Chapel Hill, North Carolina 27514, United States
  • Royal Brisbane Hospital; Clinical Haematology
    Brisbane, Queensland 4029, Australia
  • Royal Adelaide Hospital; Haematology Clinical Trials
    Adelaide, South Australia 5000, Australia
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Hokkaido University Hospital
    Hokkaido, 060-8648, Japan
  • Nara Medical University Hospital
    Nara, 634-8522, Japan
  • National Center for Child Health and Development
    Tokyo, 157-8535, Japan
  • Tokyo Medical University Hospital
    Tokyo, 160-0023, Japan
  • Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych
    Warsaw, 02-776, Poland
  • Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku
    Wrocław, 50-367, Poland
  • Hospital Universitario la Paz; Servicio de Hematologia
    Madrid, 28046, Spain
  • Hospital Universitario Virgen del Rocio; Servicio de Hematologia
    Sevilla, 41013, Spain
  • Hospital Universitario la Fe; Servicio de Hematologia
    Valencia, 46026, Spain
09

References and documents

Publications

  • Kruse-Jarres R, Peyvandi F, Oldenburg J, Chang T, Chebon S, Doral MY, Croteau SE, Lambert T, Kempton CL, Pipe SW, Ko RH, Trzaskoma B, Dhalluin C, Bienz NS, Niggli M, Lehle M, Paz-Priel I, Young G, Jimenez-Yuste V. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv. 2022 Dec 27;6(24):6140-6150. doi: 10.1182/bloodadvances.2022007458. PubMed 35939785 ↗
  • Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jimenez-Yuste V. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16. PubMed 31003963 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Dec 2017, 10 months.

Results were first posted in Dec 2018, 1 year after primary completion.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 10 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2016
First posted
Jan 13, 2017
StartActual
Jan 30, 2017
Primary completionActual
Dec 15, 2017
CompletionActual
Jun 29, 2022
Results first posted
Dec 26, 2018
Last update
Jan 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03020160
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 13, 2017
Start date
Jan 30, 2017
Primary completion
Dec 15, 2017
Completion
Jun 29, 2022
Results posted
Dec 26, 2018
Last update
Jan 11, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emicizumab

Start the discussion